<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(1)</volume><submitter>Nijm LM</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>This study sought to compare the efficacy of OC-01 (varenicline solution) nasal spray for treatment of dry eye disease (DED) in postmenopausal women (PM+) versus women who were not postmenopausal (PM-).&lt;h4>Methods&lt;/h4>This was a post hoc subgroup analysis of data integrated from two prior randomized controlled clinical trials, ONSET-1 and ONSET-2. Women randomized to treatment with OC-01 (varenicline solution) nasal spray 0.03 mg or vehicle control (VC) whose self-reported menopausal status (PM+ versus PM-) was known were included. Outcomes included the treatment difference (the OC-01 [varenicline solution] nasal spray change from baseline [CFB] minus VC CFB) in Schirmer test score (STS, mm) with anesthesia and the eye dryness score (EDS) measured on a 100-mm visual an</pubmed_abstract><journal>Ophthalmology and therapy</journal><pagination>355-364</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9834459</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials.</pubmed_title><pmcid>PMC9834459</pmcid><pubmed_authors>Hendrix LH</pubmed_authors><pubmed_authors>Nijm LM</pubmed_authors><pubmed_authors>Blemker GL</pubmed_authors><pubmed_authors>Gibson AA</pubmed_authors><pubmed_authors>Kabat AG</pubmed_authors><pubmed_authors>Hemphill M</pubmed_authors><pubmed_authors>Zhu D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials.</name><description>&lt;h4>Introduction&lt;/h4>This study sought to compare the efficacy of OC-01 (varenicline solution) nasal spray for treatment of dry eye disease (DED) in postmenopausal women (PM+) versus women who were not postmenopausal (PM-).&lt;h4>Methods&lt;/h4>This was a post hoc subgroup analysis of data integrated from two prior randomized controlled clinical trials, ONSET-1 and ONSET-2. Women randomized to treatment with OC-01 (varenicline solution) nasal spray 0.03 mg or vehicle control (VC) whose self-reported menopausal status (PM+ versus PM-) was known were included. Outcomes included the treatment difference (the OC-01 [varenicline solution] nasal spray change from baseline [CFB] minus VC CFB) in Schirmer test score (STS, mm) with anesthesia and the eye dryness score (EDS) measured on a 100-mm visual an</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-04T14:29:53.202Z</modification><creation>2025-04-04T14:29:53.202Z</creation></dates><accession>S-EPMC9834459</accession><cross_references><pubmed>36401081</pubmed><doi>10.1007/s40123-022-00607-7</doi></cross_references></HashMap>